Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

dexamethasone

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

GCR agonist

Related drugs:

‹

dexamethasone tablets (1)

dexamethasone acetate high-dose (0)

dexamethasone injection (0)

methylprednisolone acetate (0)

methylprednisolone oral (0)

methylprednisolone sodium succinate (0)

prednisolone (0)

dexamethasone tablets (1)

dexamethasone acetate high-dose (0)

dexamethasone injection (0)

methylprednisolone acetate (0)

methylprednisolone oral (0)

methylprednisolone sodium succinate (0)

prednisolone (0)

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	venetoclax + dexamethasone Sensitive: A2 - Guideline venetoclax + dexamethasone Sensitive : A2	venetoclax + dexamethasone Sensitive: A2 - Guideline venetoclax + dexamethasone Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive : A2	vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	carboplatin + gemcitabine + rituximab + dexamethasone Sensitive: A2 - Guideline carboplatin + gemcitabine + rituximab + dexamethasone Sensitive : A2	carboplatin + gemcitabine + rituximab + dexamethasone Sensitive: A2 - Guideline carboplatin + gemcitabine + rituximab + dexamethasone Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	carboplatin + gemcitabine + dexamethasone Sensitive: A2 - Guideline carboplatin + gemcitabine + dexamethasone Sensitive : A2	carboplatin + gemcitabine + dexamethasone Sensitive: A2 - Guideline carboplatin + gemcitabine + dexamethasone Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive: A2 - Guideline Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive : A2	Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive: A2 - Guideline Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive : A2
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2
No biomarker	T Cell Non-Hodgkin Lymphoma	No biomarker	T Cell Non-Hodgkin Lymphoma	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2	carboplatin + cytarabine + dexamethasone Sensitive: A2 - Guideline carboplatin + cytarabine + dexamethasone Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	abiraterone acetate + dexamethasone Sensitive: A2 - Guideline abiraterone acetate + dexamethasone Sensitive : A2	abiraterone acetate + dexamethasone Sensitive: A2 - Guideline abiraterone acetate + dexamethasone Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	venetoclax + bortezomib + dexamethasone Sensitive: B - Late Trials venetoclax + bortezomib + dexamethasone Sensitive : B	venetoclax + bortezomib + dexamethasone Sensitive: B - Late Trials venetoclax + bortezomib + dexamethasone Sensitive : B
CRBN elevation + SPARC-L	Multiple Myeloma	CRBN elevation + SPARC-L	Multiple Myeloma	lenalidomide + azacitidine + dexamethasone Resistant: C3 – Early Trials lenalidomide + azacitidine + dexamethasone Resistant : C3	lenalidomide + azacitidine + dexamethasone Resistant: C3 – Early Trials lenalidomide + azacitidine + dexamethasone Resistant : C3
KMT2A rearrangement	B Acute Lymphoblastic Leukemia	KMT2A rearrangement	B Acute Lymphoblastic Leukemia	bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive: C3 – Early Trials bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive : C3	bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive: C3 – Early Trials bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive : C3
TP53 T175H + PIK3CA H1047R	Burkitt Lymphoma	TP53 T175H + PIK3CA H1047R	Burkitt Lymphoma	cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone Sensitive: C4 – Case Studies cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone Sensitive : C4	cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone Sensitive: C4 – Case Studies cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone Sensitive : C4
RB1 mutation	Prostate Cancer	RB1 mutation	Prostate Cancer	cyclophosphamide + dexamethasone Sensitive: C4 – Case Studies cyclophosphamide + dexamethasone Sensitive : C4	cyclophosphamide + dexamethasone Sensitive: C4 – Case Studies cyclophosphamide + dexamethasone Sensitive : C4
NOTCH1 expression	Acute Myelogenous Leukemia	NOTCH1 expression	Acute Myelogenous Leukemia	dexamethasone Sensitive: D – Preclinical dexamethasone Sensitive : D	dexamethasone Sensitive: D – Preclinical dexamethasone Sensitive : D
CPS1 overexpression + KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	CPS1 overexpression + KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	cisplatin + dexamethasone Sensitive: D – Preclinical cisplatin + dexamethasone Sensitive : D	cisplatin + dexamethasone Sensitive: D – Preclinical cisplatin + dexamethasone Sensitive : D
CPS1 overexpression + KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	CPS1 overexpression + KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	dexamethasone Sensitive: D – Preclinical dexamethasone Sensitive : D	dexamethasone Sensitive: D – Preclinical dexamethasone Sensitive : D